Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines
- 31 October 2005
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 41 (15) , 2338-2346
- https://doi.org/10.1016/j.ejca.2005.06.014
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa™, ZD1839)Biochemical Pharmacology, 2004
- Systemic treatment of advanced colorectal carcinomaEuropean Journal of Gastroenterology & Hepatology, 2004
- Extensive experience of disease control with gefitinib and the role of prognostic markersBritish Journal of Cancer, 2003
- Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsThe Oncologist, 2003
- The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell linesCancer Chemotherapy and Pharmacology, 2003
- Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT‐11 (irinotecan) in human colorectal cancer cellsInternational Journal of Cancer, 2003
- Development of ZD1839 in colorectal cancerSeminars in Oncology, 2003
- Studies with ZD1839 in preclinical modelsSeminars in Oncology, 2003
- Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839Seminars in Oncology, 2001
- EGFR and cancer prognosisPublished by Elsevier ,2001